Participant characteristics, self-report survey responses, observational data and outcome measures
| Characteristics, survey responses, observational data and outcome measures | Total sample n=173 |
| Frequency (%) | |
| Females | 68 (39.3) |
| Reason for admission: | |
| Medical | 150 (86.7) |
| Surgical | 23 (13.3) |
| Reason for medical admission: | |
| Vascular/cardiovascular | 83 (48.0) |
| Respiratory | 54 (31.2) |
| Neurologic | 17 (9.8) |
| Metabolic | 6 (3.5) |
| Gastrointestinal | 3 (1.7) |
| Other* | 10 (5.8) |
| Median (IQR) | |
| Age in years | 74 (69.0, 79.0) |
| Total comorbidities† | 3 (2.0, 5.0) |
| Discharge medications‡ | |
| Total medications prescribed per patient | 12 (9.0, 16.0) |
| Unchanged medications per patient | 8 (4.0, 12.0) |
| New medications per patient | 3 (1.0, 5.0) |
| Changed medications per patient | 0 (0.0, 1.0) |
| Ceased medications per patient | 0 (0.0, 1.0) |
| The Short Test of Functional Health Literacy in Adults‡ (possible range 3–15) | 14 (11.8, 15.0) |
| Drug-Associated Risk Tool‡ (possible range 0–34) | 23 (21.0, 24.0) |
| Euroqol Visual Analogue Scale (possible range 0–100) | 60 (50.0, 80.0) |
| Preferred role in discussing medications with healthcare professionals§: | |
| Active | 119 (69.2) |
| Passive | 53 (30.8) |
| Frequency (%) | |
| Type of healthcare professional leading medication communication during encounter: | |
| Pharmacist | 73 (42.2%) |
| Nurse | 70 (40.5%) |
| Doctor | 30 (17.3%) |
| Median (IQR) | |
| Preponderance of Initiative | 0.7 (0.5–1.0) |
| Dialogue Ratio | 0.3 (0.2–0.4) |
*Other included cellulitis, muscoskeletal disorder (back pain and constipation), genitourinary disorder and haematoma complications postinsertion of pace makers.
†See online supplemental file 4 for the taxonomy we used for recording comorbidities.
‡≤15 missing data.
§response options binarised: active = ‘I prefer that the healthcare professional and I have shared discussions about my medicines’, and ‘I prefer to lead discussion about my medicines’, passive= ‘I prefer the healthcare professionals to lead discussions about my medicines’.